Randomized, Open-Label Trial of Primaquine against Vivax Malaria Relapse in Indonesia

• DOI: 10.1128/aac.01879-12
• Publication Date: 2012-12-18T04:21:37Z
• Authors: Inge Sutanto; Bagus Tjahjono; Hasan Basri; W. Robert Taylor; Fauziah A. Putri; Rizka A. Meilia; Rianto Setiabudy; Siti Nurleila; Lenny L. Ekawati; Iqbal Elyazar; Jeremy Farrar; Herawati Sudoyo; J. Kevin Baird
• Keywords: Adult; Male; Quinine; Drug Resistance; 610; Artesunate; Primaquine; Artemisinins; Drug Administration Schedule; Malaria; 3. Good health; Antimalarials; 03 medical and health sciences; Military Personnel; 0302 clinical medicine; Indonesia; Malaria, Vivax; Quinolines; Secondary Prevention; Humans; Drug Dosage Calculations; Drug Therapy, Combination; Plasmodium vivax

ABSTRACT

Radical cure of Plasmodium vivax infection applies blood schizontocidal therapy against the acute attack and hypnozoitocidal therapy against later relapse. Chloroquine and primaquine have been used for 60 years in this manner. Resistance to chloroquine by the parasite now requires partnering other blood schizontocides with primaquine. However, the safety and efficacy of primaquine against relapse when combined with other drugs have not been demonstrated. This randomized, open-label, and relapse-controlled trial estimated the efficacy of primaquine against relapse when administered with quinine or dihydroartemisinin-piperaquine for treatment of the acute infection. Among 650 soldiers who had returned to their malaria-free base in Java, Indonesia, after 12 months in malarious Papua, Indonesia, 143 with acute P. vivax malaria were eligible for study. One hundred sixteen enrolled subjects were randomized to these treatments: artesunate (200-mg dose followed by 100 mg/day for 6 days), quinine (1.8 g/day for 7 days) plus concurrent primaquine (30 mg/day for 14 days), or dihydroartemisinin (120 mg) plus piperaquine (960 mg) daily for 3 days followed 25 days later by primaquine (30 mg/day for 14 days). Follow-up was for 12 months. One hundred thirteen subjects were analyzable. Relapse occurred in 32 of 41 (78%) subjects administered artesunate alone (2.71 attacks/person-year), 7 of 36 (19%) administered quinine plus primaquine (0.23 attack/person-year), and 2 of 36 (6%) administered dihydroartemisinin-piperaquine plus primaquine (0.06 attack/person-year). The efficacy of primaquine against relapse was 92% (95% confidence interval [CI] = 81% to 96%) for quinine plus primaquine and 98% (95% CI = 91% to 99%) for dihydroartemisinin-piperaquine plus primaquine. Antirelapse therapy with primaquine begun a month after treatment of the acute attack with dihydroartemisinin-piperaquine proved safe and highly efficacious against relapse by P. vivax acquired in Papua, Indonesia.